The Accelerating Medicines Partnership in Common Metabolic Diseases (AMP-CMD) is a public-private partnership to identify drivers of common metabolic diseases, including nonalcoholic steatohepatitis, chronic kidney disease, obesity, atherosclerotic cardiovascular disease and heart failure, type 2 diabetes/prediabetes, autoimmune diabetes, and inflammation. AMP-CMD supports the generation and analysis of genetic association results, epigenomic annotations, and functional studies, and the representation of these results in the open-access Common Metabolic Diseases Knowledge Portal. In keeping with the model of multi-institution collaboration on which AMP-CMD is based, we are opening the Funding Opportunity described below to researchers outside of the AMP-CMD consortium.
The current 5-year AMP-CMD award includes funding for an annual opportunity pool (OP) to support projects to address research directions that would further consortium goals but are not currently ongoing in the consortium. The OP comprises $500,000 total cost for each of the 5 years of the AMP-CMD award. The OP funds are allocated from the NIDDK limited competition award (UM1DK105554), and OP project awards are administered by the Broad Institute. In the first round (Fall 2021), applications for years 1 and 2 are being considered. We anticipate that calls for applications in future rounds (years 3-5) will occur in January or February of 2022-2024.
Potential research areas for OP funding are identified by surveying the AMP-CMD NIDDK Steering Committee to identify gaps in current research, which are then prioritized with guidance from NIDDK. This survey and prioritization process will be repeated for each new OP funding period (i.e., each year). In the first funding cycle, 3 broad themes were identified:
THEME 1: Assessment of additional tissues that are not currently included in the consortium activities (adipose, islets, muscle, liver) but are central to T2D (e.g. brain regions, intestines, immune cells)
THEME 2: Developing resources for functional characterization that are widely applicable across tissues/cells of interest.
THEME 3: Developing computational tools to enhance the ongoing efforts to identify T2D related signals and prioritize variants for functional characterization
AMP-CMD now invites proposals for projects to be supported in the first two years of the OP. For years 1 and 2 of the OP we have elected to focus on Theme 2; therefore we invite proposals for the development of resources for functional characterization that are widely applicable across a broad range of tissues and cells, such as libraries of reporters, oligos, gene perturbation reagents, 3-D organoid models, or stem cell lines. Future funding cycles will focus on additional themes.
Proposals are due on Oct 25, 2021. Details on how to apply are available in the Opportunity Pool Handbook. Please direct any inquiries to "amp-cmd-opportunity-pool(at)broadinstitute.org".